Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Subscribe To Our Newsletter & Stay Updated
